Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...

Maternal cannabis use puts kids at risk of behavioural problems

Children exposed to their mother's cannabis use during pregnancy and after birth are three...

Content from other channels on our network

Western Sydney Local Health District prosecution withdrawn

Bankstown-Lidcombe and Liverpool Hospitals trial body cameras

Brain and kidney injury treatment after cardiac surgery

Gentle care practices to help reduce pressure injury risk factors

Optimising surface cleaning chemical storage in healthcare

Aussie manufacturing conditions improve at fastest pace since 2022

The engineering workforce is critical to securing Australia's future

The future of automation: Siemens SIMATIC S7-1200 G2

Study shows coal mine methane emissions much higher than reported

Boral secures grant for cement kiln carbon reduction

Wannon Water solves pump blockage issue

STABILISOR tech revolutionises air compressor operation

Kate Ceberano helps raise over $580,000 for clean water

Consult Australia Awards — winners announced

Land water loss causes sea level rise in 21st century